The rationale for liquid biopsy in colorectal cancer: focus on circulating tumor cells by Gazzaniga, Paola et al.
This article was downloaded by: [Universita Studi la Sapienza], [Chiara Nicolazzo]
On: 20 May 2015, At: 01:54
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House,
37-41 Mortimer Street, London W1T 3JH, UK
Expert Review of Molecular Diagnostics
Publication details, including instructions for authors and subscription information:
http://www.tandfonline.com/loi/iero20
The rationale for liquid biopsy in colorectal cancer: a
focus on circulating tumor cells
Paola Gazzanigaa, Cristina Raimondia, Chiara Nicolazzoa, Raffaella Carlettib, Cira di Gioiab,
Angela Gradilonea & Enrico Cortesib
a 1Dipartimento di Medicina Molecolare, Sapienza Università di Roma, Roma, Italy
b 2Dipartimento di Scienze Radiologiche, Oncologiche ed Anatomopatologiche, Sapienza
Università di Roma, Roma, Italy
Published online: 15 May 2015.
To cite this article: Paola Gazzaniga, Cristina Raimondi, Chiara Nicolazzo, Raffaella Carletti, Cira di Gioia, Angela Gradilone
& Enrico Cortesi (2015): The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells, Expert Review
of Molecular Diagnostics
To link to this article:  http://dx.doi.org/10.1586/14737159.2015.1045491
PLEASE SCROLL DOWN FOR ARTICLE
Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained
in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no
representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the
Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and
are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and
should be independently verified with primary sources of information. Taylor and Francis shall not be liable for
any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever
or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of
the Content.
This article may be used for research, teaching, and private study purposes. Any substantial or systematic
reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any
form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://
www.tandfonline.com/page/terms-and-conditions
The rationale for liquid
biopsy in colorectal cancer:
a focus on circulating
tumor cells
Expert Rev. Mol. Diagn. Early online, 1–8 (2015)
Paola Gazzaniga*1,
Cristina Raimondi1,
Chiara Nicolazzo1,
Raffaella Carletti2,
Cira di Gioia2,
Angela Gradilone1 and
Enrico Cortesi2
1Dipartimento di Medicina Molecolare,
Sapienza Universita` di Roma,
Roma, Italy
2Dipartimento di Scienze Radiologiche,
Oncologiche ed Anatomopatologiche,
Sapienza Universita` di Roma,
Roma, Italy
*Author for correspondence:
Tel.: +39 6 4451286
paola.gazzaniga@uniroma1.it
Capturing circulating tumor cells (CTCs) and/or circulating tumor DNA from blood, which
represents a precious source of biological material derived from both primary and metastatic
tumors, has been named a ‘liquid biopsy’. While the circulating tumor DNA might be more
representative of the bulk of the metastatic tumor, CTCs are thought to reflect more of the
metastases-initiating cells. Consequently, a liquid biopsy made of tumor cells and tumor
DNA that is able to track cancer evolution, as a fingerprint of the patient’s individual tumor,
and is easy to perform at every stage of the disease course, sounds attractive. This article
mainly focuses on the applications of CTCs to track tumor dynamics in real time using
colorectal cancer as a model system. The analysis of viable CTCs at DNA, RNA and protein
levels, as well as their expansion in vitro, may allow deep investigation of the features of
metastases-initiating cells.
KEYWORDS: cancer stem cells . circulating tumor cells . colorectal cancer . epithelial–mesenchymal transition . liquid
biopsy . targeted therapy
The innovative and exciting idea that most
solid tumors spread tumor cells into the blood-
stream, which can be quantified through enu-
meration and provide information about
prognosis, recently celebrated its tenth birthday.
Capturing circulating tumor cells (CTCs)
and/or circulating tumor DNA (ctDNA) from
blood, which represents a precious source of
biological material derived from both primary
and metastatic tumor, has been named ‘liquid
biopsy’. While the ctDNA might be more rep-
resentative of the bulk of the metastatic
tumor [1], CTCs are thought to reflect more of
the metastases-initiating cells. Compared to the
traditional tissue biopsy, which represents a
static snapshot of a tumor, a liquid biopsy has
a unique, great advantage: to provide a ‘real
time’ information on disease burden, shedding
light on tumor evolution over time and on its
heterogeneity. Due to the difficulty of repeated
sampling of tumors and corresponding meta-
static lesions, liquid biopsy is expected to
improve understanding and monitoring of
changes in tumor cell populations during dis-
ease progression and, more crucial, in response
to therapies. In fact, although it is largely
accepted that intra-tumor heterogeneity might
influence the effectiveness of molecular targeted
therapy, the major barrier to investigate the
acquired drug resistance is the frequent unavail-
ability of post-treatment tumor samples. Con-
sequently, a liquid biopsy made of tumor cells
and tumor DNA able to track cancer evolu-
tion, as a fingerprint of patient’s individual
tumor, easy to perform in every stage of the
disease course, sounds attractive. This perspec-
tive mainly focuses on the applications of
CTCs to track tumor dynamics in real time
using colorectal cancer (CRC) as a model sys-
tem. The analysis of viable CTCs at DNA,
RNA and protein levels, as well as their expan-
sion in vitro, may allow us to deeply investigate
the features of metastases-initiating cells.
Liquid biopsy & new therapeutic targets:
lessons from CRC stem cells
Dreaming about the optimal anti-cancer treat-
ment, the ultimate goal of therapies should be
the radical elimination of all tumor cells. In
the face of the rapidly emerging and complex
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cancer heterogeneity now coming into focus, it is not surprising
that this goal is hard to be reached [2]. In the last few decades,
the old model of cancer clonal evolution, stating that all cancer
cells have the same ability to acquire genetic and/or epigenetic
changes, conferring growth advantage, has been challenged by
the cancer stem cells (CSCs) hypothesis [3]. The new model
suggests that tumors are highly hierarchical with a unique
self-renewing population of putative CSCs at the top of the
hierarchy, which are thought to drive tumor propagation and
metastatic relapse, mainly due to their ability to self-renew and
escape traditional therapies. Accumulating evidence has sug-
gested that both models might be easily combined towards a
dynamic model where clonal evolution and CSC models are
both involved in cancer progression [3]. In CRC, it has been
suggested that these cells may sustain colon cancer progres-
sion [4]. The self-renewal capacities of colon CSCs have been
ascribed to different pathways, including that of Wnt, Notch
and HGF. Poorly differentiated CRCs have an increased num-
ber of CSCs, and the epithelial–mesenchymal transition (EMT)
induced by the tumor microenvironment seems to favor CSCs
expansion [5]. To date, the search for CSC markers is based on
the presence of antigens on subpopulation of cells with stem-
like properties. Despite the powerful search for surface markers
specific for CRC CSC, the results are currently inconsistent.
This failure may be ascribed to the plasticity of CRC CSCs
phenotype, which strongly depends upon several variables,
including the selective pressure of therapies, the type of therapy
and unpredictable microenvironmental factors. In this interpre-
tation, the originating CSC that sustained the first oncogenic
mutation gives rise to subclones with self-renewal capabilities
that accumulate epigenetic and genetic changes over time. Each
different CSC subclone gives rise to intermediate transit-
amplifying progenitors that lack self-renewal capabilities. This
instability allows CSC to unceasingly move from a functional
state to another, even floating between a stem and non-stem
state [6]. This suggests that, being both CSCs and non-CSCs
highly adaptable populations capable of transient evolution and
plasticity, targeting both is imperative. CD133, CD44, CD24,
CDCP1, CXCR4, CD44v6, CD44v9 and CD26 have been
identified as colon CSC surface antigens, but it is not well
defined which are the best markers to identify a tumor stem
cell [7–11]. From a mere experimental point of view, the CSC
model has been always tested using mouse transplantation
assays, which undoubtedly underestimate the frequency of cells
with metastatic potential due to the persistence of xenogeneic
immune response even in immunocompromised animals, and
to the different microenvironment, being human cancer cells
forced to grow in a mouse environment (e.g., inability of
murine growth factor to bind human receptor). In CRC, the
use of xenotransplantation in immunocompromised mice as
functional assays for studying CSCs recently leads to the dem-
onstration that tumorigenic activity is confined in the
CD44v6 population, which also shares EMT features [9]. Fol-
lowing this observation, our group is currently investigating
whether CD44v6 might be retained in CTCs isolated through
a filtration method (ScreenCell) from patients with metastatic
CRC (mCRC). Our preliminary data suggest that a subpopula-
tion of CTCs expressing CD44v6 are detectable through a
liquid biopsy, thus supporting the hypothesis that the CTC
population contains putative CSCs, and lightening the possibil-
ity of an easily reproducible liquid biopsy to develop new
CSC-targeted drugs in CRC (data submitted for publication).
Obviously, in a liquid biopsy what we expect to find is a mixed
population of innocent, bystander CTCs and more aggressive
circulating CSCs with EMT traits. Evidence exists that in CRC
dedifferentiated cancer cells combine EMT properties with a
stem cell-like phenotype, leading to the hypothesis that these
cells combine traits that are necessary for acquiring motility
and a stem-like phenotype [12]. Therefore, the identification of
‘circulating CSCs’ in the entire pool of tumor cells dissemi-
nated in the bloodstream would, at least theoretically, provide
a unifying hypothesis on CTCs and CSCs. In this context,
recent data indicate that CSCs and CTCs may represent differ-
ent functional statuses of the same pathogenically relevant sub-
population of cancer cells [13] and proteomic research, as well
as single cell sequencing may contribute to differentiate
bystander CTCs from cancer circulating stem cells with rapid
clinical applications in diagnosis, prognosis and therapies. It is
conceivable that the elimination of bystander CTCs by
immune system or chemotherapy may impair the balance
between CTCs and CSCs thus selecting aggressive subclones,
similar to what observed in primary and metastatic tumors.
The more lines of therapy one patient receives, the more likely
the circulating CSCs may be selected. Thus, trying to imagine
an ideal liquid biopsy-directed therapy in CRC, the combina-
tion of existing chemotherapeutic drugs with a CSC targeting
agent might be conceived to eliminate both bystander CTCs
and circulating CSCs, including those that may have become
dormant. Unfortunately, the identification of circulating CSCs
relies on the same putative stem cell markers previously identi-
fied in CSC. These markers are highly imperfect so that even
isolating a marker-positive subpopulation that is CSC rich, we
cannot exclude the presence of CSC in the marker-negative
subpopulation, which will re-establish a marker-positive sub-
population in the tumor. Furthermore, the use of a broad spec-
trum of different antigen-dependent and antigen-independent
methods, which may capture different populations of CSCs in
the pool of CRC CTCs, may add complexity in the identifica-
tion of specific stem-like markers [14–16].
Liquid biopsy & molecular subtypes of CRC:
questioning about EMT
The recent molecular subtype classification of CRC highlighted
three distinctive hallmarks: EMT, higher mutation frequency
and cellular proliferation [17]. The mismatch repair deficient
subtype (A type) displays strong microsatellite instability phe-
notype and epithelial features; it accounts for 20–30% of all
CRC and benefits from 5-fluorouracil-based chemotherapy.
More than half cancers with epithelial phenotype are character-
ized by high proliferation rate and low overall mutation
Review Gazzaniga, Raimondi, Nicolazzo et al.
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frequency, consistent with the absence of DNA mismatch
repair deficiency. Patients with this subtype (B type) show a
relatively poor baseline prognosis but benefit most significantly
from adjuvant chemotherapy, due to the high proliferation rate
of tumor cells. The third class (C-type), which has a mesenchy-
mal gene expression phenotype, is enriched with genes indica-
tive of a stem-like state and characterized by low proliferative
index, thus resistant to conventional treatments. Further studies
have now well established that tumors defined by these three
groupings can be additionally stratified into further molecularly
defined subtypes, with unifying feature being the identification
of a CRC subtype significantly enriched for genes associated
with a poorly differentiated, mesenchymal/invasive phenotype,
often co-enriched with genes indicative of a stem-like state [18].
Thus, regardless of the molecular classification used, it is
accepted that a mesenchymal signature is a defining feature of
poor prognosis in CRC. EMT is involved in all steps of meta-
static cascade, from the escape from primary site, where micro-
environmental and genetic factors endorse the activation of
EMT program, to the intravasation where epithelial–mesenchy-
mal-transitioned cells are transported in the circulation to the
latter formation of micrometastases. The consequent coloniza-
tion in distant organs requires the reversion of EMT and/or
activation of the MET program to establish secondary
tumors [19]. The frequent association between EMT and perito-
neal carcinomatosis in CRC is a further proof that EMT-
positive tumors have high metastatic potential, which is partic-
ularly important even at early stages of tumor growth [20]. The
mechanisms for maintenance of mesenchymal state in CTCs
are not fully understood, although it has been described that
mesenchymal CTCs may be clustered with platelets, which rep-
resent the major source of circulating TGF-b production, a pri-
mary inducer of EMT [21]. It is conceivable that CTCs need to
maintain the EMT program to prevent anoikis while in circula-
tion, and use their mesenchymal features to protect themselves
from many chemotherapy as well as molecularly targeted drugs.
EMT is associated with resistance to gemcitabine, 5-fluoroura-
cil, cisplatin, tyrosine kinase inhibitors and hormonal ther-
apy [22]. The presence of mesenchymal cells has been
consistently found associated with resistance to monoclonal
anti-EGFR antibodies (Cetuximab), as mesenchymal cells regu-
late AKT activation through EGFR-independent pathways like
integrin-linked kinase. Consistent with these findings, several
studies have highlighted the prognostic significance of CRC
CTCs with EMT features, suggesting that the genetic makeup
of these cells would be useful for the discovery of new
‘druggable’ targets [23,24]. Actually, since it is emerging that
both epithelial and mesenchymal tumor cells need to cooperate
to successfully form metastatic tumors (only the epithelial-like
are able to generate macrometastases, which are consequently
largely epithelial), targeting both cell types, combining standard
chemotherapies against cycling cells with EMT inhibitors
would improve therapeutic success. Among the EMT-inhibiting
approaches, targeting circulating mesenchymal cells could be
considered. For example, Twist silencing, which has been
demonstrated to reduce the number of CTCs with EMT phe-
notype in prostate cancer, might be exploited therapeutically,
even if it might elicit an acceleration of epithelial cell deposits
with increased metastasis formation [25]. Recent studies per-
formed in breast cancer have provided evidence of a striking
association between expression of mesenchymal markers and
clusters of CTC rather than single migratory cells [26]. These
clustered CTCs, which have the cell junction component pla-
koglobin highly differentially expressed compared to single
CTCs, are oligoclonal precursors of breast cancer metastasis.
Whether the presence of CTC clusters may have a role in
CRC has been poorly investigated, although this item should
deserve more attention [27]. Through the filtration-based
method ScreenCell we were able to detect CTC clusters from
patients with mCRC (FIGURE 1). These clusters were found
enriched with mesenchymal-like cells (FIGURE 2). CTC clusters
are described to travel into the bloodstream ‘protected’ by pla-
telets, which are believed to promote their survival within the
circulation allowing them to escape the immune surveillance.
Furthermore, recent studies have provided evidence that
platelets-derived TGF-b and PDGF are powerful activators of
EMT in CTCs [21]. In this scenario, and thinking about the
prolonged survival of CRC patients treated with aspirin, a
new appealing role of aspirin as a modulator of platelet-
induced EMT in CTC clusters could be speculated, which
may contribute to the intriguing antimetastatic potential of
this drug. The use of new filtration methods capable of viable
enrichment of single and clustered CTCs from clinically
Figure 1. Cluster isolated from a liquid biopsy of a
metastatic colorectal cancer patient. CTCs were isolated
through a filtration-based method (ScreenCell). After blood
filtration, the filter was stained with Giemsa, and analyzed by a
pathologist. Giemsa staining enables morphological analysis of
potential CTCs.
CTCs: Circulating tumor cells.
The rationale for liquid biopsy in CRC Review
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relevant volumes of whole blood could address this crucial
question [28].
Liquid biopsy & targeted therapy: catching a ‘moving
target’ in CRC
The improved understanding of CRC molecular biology and
the recent advances in diagnostic techniques and tailored thera-
pies have approximately tripled median survival of patients
with mCRC in the last two decades. Cetuximab and panitu-
mumab, both targeting the EGFR, have largely contributed to
this success. Both drugs are indicated for wild-type (WT)
KRAS mCRC, due to the recognition that activating mutations
in KRAS is a strong predictor of resistance to EGFR-targeted
mAbs. Thus, routine testing of all patients with CRC for
KRAS mutations is now recommended; only those harboring
WT KRAS should be candidates for such therapies, thus
improving outcomes, and minimizing unnecessary toxicity and
cost. Although KRAS testing has facilitated the selection of
patients who are most likely to have a response to anti-EGFR
therapy, a substantial fraction of patients with WT-RAS tumors
do not benefit from treatment [29]. Resistance to anti-EGFR
therapies, which typically occur within 3–18 months after treat-
ment initiation, is partly ascribed to oncogenic activation of
other intracellular signaling pathways (RAS/RAF/MAPK; PI3K/
PTEN/AKT), acting downstream and/or independently of
EGFR [30]. Thus, although EGFR-targeting therapies are key
approaches in the treatment of mCRC patients, the adaptation
of tumor cells to these molecularly targeted agents still repre-
sents a significant barrier towards an effective treatment, as
demonstrated by the short duration of clinical benefit in the
majority of patients with advanced disease. The success of indi-
vidualized cancer treatments is furthermore limited by the sig-
nificant variability of biomarkers expression within primary and
metastatic tumors. Although at present
KRAS mutational status is the only pre-
dictive marker for targeted therapy in
mCRC, the concordance in KRAS muta-
tion status between primary colorectal
tumors and metastases still remains a
controversial issue. Notably, although
most studies agree on high rate of con-
cordance, which is congruent with the
notion that KRAS mutations are consid-
ered early driving events in CRC progres-
sion, a recent meta-analysis showed that
around 11% of patients with mutant
KRAS in the primary tumor, thus not
candidate for targeted therapy, have WT-
KRAS in the metastases, and that 9% of
patients with WT-KRAS in the primary
tumor have mutant KRAS in the meta-
static site [31]. The clinical relevance of
these percentages seems considerable, in
light of the 40% of patients harboring
KRAS mutations within the entire popu-
lation of patients with CRC. The explanations for such vari-
ability in biomarker expression between primary tumor and
metastasis might be numerous. Anti-EGFR therapy has been
shown to promote the selection of RAS mutant subclones in
primary tumors that are otherwise KRAS, NRAS and BRAF
WT. The complex cancer heterogeneity translates in a substan-
tial instability of cancer genomes, enabling cancer cells to adapt
to any hostile environment under selective pressures, including
the application of targeted therapies, and driving the evolution
of resistant subclones. Often clinical practice is guided by the
molecular analysis of primary tumors assuming that all primary
tumor characteristics are carried over to metastases later in the
disease course. Nevertheless, according to the two models of
metastatic dissemination, a late dissemination following a sub-
clonal selection at the primary site should be taken into
account to explain the deviation of genetic makeup from a pri-
mary to a metastatic cancer. Single biopsy specimens of pri-
mary tumors performed for diagnostic purposes may not be
sufficiently sensitive to detect genetic events in tumor sub-
clones. In the case of mKRAS metastases derived from WT-
KRAS primary tumors, the hypothesis that cancer cells may
have detached from the primary tumor before the acquisition
of KRAS mutation should also be taken into account. Recent
studies support that relapse in mCRC patients treated with
anti-EGFR therapies may be due to the growth of cells with
low, thus undetected, KRAS mutant tumor cell content [29,32].
In this perspective, the authors conclude that few if any colon
tumors are WT, with intriguing implications for effective tar-
geted therapy. All these data together confirm that, being can-
cer genotypes highly plastic and unstable, an adjustment of
molecularly targeted therapies to reflect such continuous genetic
alterations is strongly needed and that some mCRC patients
may require serial monitoring of their tumor genome’s makeup
DAPI 40X Vimentin 40X CK20 40X
Figure 2. Immunofluorescence of liquid biopsy from one mCRC patient showing
vimentin expression as a hypothetical marker of EMT, and CK-20 as a marker
of colorectal cancer. The blue counterstaining (DAPI) shows the location of nuclei
(Magnification 40).
mCRC: Metastatic colorectal cancer; EMT: Epithelial–mesenchymal transition.
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to warrant that the therapy is still ‘hitting the target’ or to
detect whether new predictive biomarkers are emerging. The
recent observation that WT-KRAS primary tumors shed into
circulation circulating free tumor DNA with mKRAS sequenc-
ing few months after starting treatment suggests that a liquid
biopsy may address the temporal heterogeneity of activating
KRAS mutations, identifying early the appearance of KRAS
mutant tumor cells over the course of the disease [33]. The very
high concordance found in the first blinded prospective study
comparing the determination of KRAS and BRAF mutation
status from ctDNA to that determined from tumor-tissue anal-
ysis is a demonstration that liquid biopsy through ctDNA anal-
ysis could advantageously replace tumor-section analysis. A key
question to be solved concerning ctDNA is which populations
of cells it actually reflects. Is it released from apoptotic/necrotic
tumor cells (if this is the case its burden would reflect the effi-
cacy of therapies) or is it actively secreted (if this is the case its
burden would reflect the resistance to therapies)? This last
hypothesis to date is still enigmatic. Our group recently investi-
gated KRAS pathway activating mutations in CTCs and deter-
mined the degree of heterogeneity for KRAS oncogenic
mutations between CTCs and tumor tissues [34]. Whether
KRAS gene amplification may represent an alternative pathway
responsible for KRAS activation was also explored. KRAS gene
amplification emerged as a functionally equivalent and mutu-
ally exclusive mechanism of KRAS pathway activation in
CTCs, possibly related to transcriptional activation. Discor-
dance in KRAS mutational profile has been widely demon-
strated between primary CRC and CTCs. In this case, the
serial assessment of CTCs mutational profile may represent a
clear biomarker for treatment resistance, able to overcome the
intrinsic limit of ctDNA discussed above. The fact that CTCs
are live cells is the main advantage of their use in liquid biopsy.
In fact, literal meaning of the term ‘liquid biopsy’ should be
restricted to a blood test that is associated with cytopathological
assessment, by analogy to the definition of a ‘tissue’ biopsy. By
the same analogy, a liquid biopsy should theoretically be able
to provide clear images of tumor cells to the pathologist, using
conventional staining methods, and to allow pathologist to per-
form a diagnosis through the identification of morphological
features and immunohistochemical markers of prognostic rele-
vance. Of note, we might use liquid biopsy to verify whether
the well-defined molecular subtypes of CRC, each with distinct
features and prognostic significance, are maintained in CTCs
throughout the metastatic process, with the additional possibil-
ity for downstream genetic analyses using whole genomic
amplification. To this purpose, novel blood filtration techni-
ques suited for cytomorphological classification, immunocyto-
chemical and molecular characterization of CTCs, where
staining, cell enumeration, immunocytochemistry and FISH
assays can be conducted directly on the filter, represent an easy,
economic, rapid tool to deep insight microheterogeneity of
CRC [35–39]. Angiogenesis is the other one validated therapeutic
target in CRC patients with macroscopic metastases. On the
molecular level, it is controlled by a number of pro- and anti-
angiogenic factors, among which the VEGF signaling plays a
pivotal role [40]. Despite the proven benefit of VEGF-targeting
therapy in metastatic setting, the modest effects observed in
adjuvant setting, the high variability in individual patient
response and the frequent appearance of acquired resistance
again reflect the complex CRC heterogeneity in angiogenesis
pathways. This heterogeneity, again, might not be captured by
the tumor biopsy performed before first treatment, since single
portions of a tumor may be differently vascularized. Whether
metastatic tumors may be more dependent on angiogenesis
than micrometastases is one of the unsolved questions which
might partially explain the failure of the anti-VEGF monoclo-
nal antibody Bevacizumab in adjuvant setting [41]. The role of
circulating endothelial cells as a potential biomarker of efficacy
of antiangiogenic therapies has been widely investigated
through CellSearch system, which reached a sufficient level of
sensitivity for circulating endothelial cell quantification and
monitoring during the course of the disease and in response to
treatment [42]. Results from clinical trials investigating the pre-
dictive role of circulating endothelial cell in CRC patients
treated with antiangiogenic therapies are conflicting and thus
deserve further attention.
Expert commentary
Investigating complexities of cancer heterogeneity both at pri-
mary and metastatic sites is increasingly coming into focus.
Recent evidence has been provided that a high degree of
heterogeneity is also observed in cancer cells traveling in the
bloodstream. The concept of CTCs heterogeneity hampers the
necessity to isolate the different entities found in the blood and
to analyze them comparatively to investigate the tumorigenic
potential of different subsets, thus moving away from the prog-
nostic significance of their enumeration, well proven in differ-
ent tumor types, including colon cancer. To this purpose, the
identification of a recently proved stem-like marker of colon
cancer, CD44v6, in CTCs from mCRC patients who failed
second line therapies may suggest that this specific CTCs sub-
population could theoretically drive CRC progression. Never-
theless, to be confirmed, this hypothesis needs to be assessed in
CTCs-derived xenograft tumor models, which to date represent
the most reproducible approximation of human tumors. In this
context, the recent establishment of a stable CTC line from the
blood of a metastatic colon cancer patient, which showed a
complex genetic makeup made of epithelial, mesenchymal and
stem-like features, as well as tumorigenic potential after xeno-
grafting into immunodeficient mice, has particular relevance [43].
Established CTC lines from CRC patients will be really helpful
to investigate drug resistance as well as in future might facilitate
new drug development. Nevertheless, the low success rate of
CTC lines generation, the rarity of metastasis initiating cells
frequency within CTCs pool, the lack of specific CSCs markers
and the divergence between murine and human microenviron-
ments hamper the necessity to optimize the ex vivo culture con-
ditions of these cells. Further studies exploring the tumorigenic
potential of single CTCs compared to clusters are also
The rationale for liquid biopsy in CRC Review
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warranted. To date, the role of CTC clusters in colon cancer
has been poorly investigated. To this purpose, the cross talk
between platelets and CTCs, the effects of specific anti-platelets
compounds to block this cross talk, as well as the role of
platelets-derived endostatin and TGF-b in CTCs cluster main-
tenance might represent a fertile ground of investigation.
Five-year view
Cancer research is rapidly moving. Patients are increasingly
treated with molecularly targeted approaches aimed to block
crucial cancer drivers, based on the genomic characteristics of
the primary tumor. In light of the increasing knowledge about
tumor heterogeneity, it is clear that single biopsy tumor resec-
tion does not accurately reflect the overall portrait of a patient’s
cancer, thus hampering the search for solid biopsy surrogates
that may accurately represent the real-time status of the
patient’s tumor. In CRC, studies performed using ctDNA and
CTCs suggest that in a next future we may use a combination
of both as liquid biopsies to provide new insight into targeted-
therapy efficacy, metastatic competence and cancer heterogene-
ity. The use of liquid rather than conventional biopsy might
circumvent the spatial bias of sample collection, and the limited
access to matched pretreatment and post-treatment tissues.
Nevertheless, whether this approach may lead to a positive dif-
ference for patient’s care is still to be determined with large
clinical trials. The continuous plasticity of CTCs, continuously
floating between EMT/non-EMT as well as stem-like/non-
stem-like state, represents a major obstacle to their identifica-
tion and targeting for clinical purpose. CTCs heterogeneity
and plasticity hamper the use of combination of agents, includ-
ing blockage of various self-renewal pathways (Wnt, Notch,
PTEN and Hedgehog) or new approaches which may force
cells to escape EMT induction, thus contributing to the deple-
tion of cells with stem-like/EMT features, such as
CD44v6 positive clones. The high degree of heterogeneity
described in CTCs also implies that new multimarker assays
are necessary to reveal the real diagnostic potential of blood-
based tests. Furthermore, innovative imaging technologies
should be developed to determine the effects of hypothetical
CSC-targeting drugs, since tumor shrinkage cannot be consid-
ered a measure for their efficacy. Finally, the development of
nanoparticles and nanoformulations to be used for CTCs neu-
tralization is an innovative, appealing tool [44].
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Key issues
. Liquid biopsy might provide ‘real time’ information on disease burden, shedding light on tumor evolution over time and on its
heterogeneity.
. In colorectal cancer (CRC), the enumeration of circulating tumor cells (CTCs) for prognostic purpose needs to be explored in non-
metastatic setting, specifically high risk stage II CRC patients, where the role of adjuvant therapy is debated.
. In metastatic setting a comparison between the ‘all-RAS’ mutational status of primary tumor and that of liquid biopsy is potentially
useful to follow cancer evolution as a ‘moving target’.
. The finding of CD44v6 positive CTCs in bloodstream of metastatic CRC patients supports the hypothesis that the CTC population
contains CSCs, and lightens the possibility of an easily reproducible liquid biopsy to develop new CCSC-targeted drugs in CRC.
. CTC clusters are described to travel into the bloodstream ‘protected’ by platelets, which are believed to be powerful activators of
epithelial–mesenchymal transition in CTCs through TGF-b and PDGF pathways.
. The analysis of circulating clusters in metastatic CRC through liquid biopsies might allow us to explore a new role of aspirin and anti-
platelet drugs as modulators of epithelial–mesenchymal transition features in CTCs.
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